Medidata Solutions Inc. (MDSO) President Vries Glen Michael De Sells 7,500 Shares
Medidata Solutions Inc. (NASDAQ:MDSO) President Vries Glen Michael De sold 7,500 shares of the business’s stock in a transaction on Tuesday, October 11th. The shares were sold at an average price of $54.72, for a total transaction of $410,400.00. Following the sale, the president now directly owns 942,653 shares of the company’s stock, valued at $51,581,972.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Vries Glen Michael De also recently made the following trade(s):
- On Monday, September 12th, Vries Glen Michael De sold 7,500 shares of Medidata Solutions stock. The shares were sold at an average price of $53.70, for a total transaction of $402,750.00.
- On Tuesday, August 9th, Vries Glen Michael De sold 7,500 shares of Medidata Solutions stock. The shares were sold at an average price of $54.39, for a total transaction of $407,925.00.
Shares of Medidata Solutions Inc. (NASDAQ:MDSO) opened at 52.32 on Friday. Medidata Solutions Inc. has a 1-year low of $30.22 and a 1-year high of $57.21. The stock has a market capitalization of $2.91 billion, a P/E ratio of 134.50 and a beta of 1.29. The company has a 50 day moving average price of $55.00 and a 200-day moving average price of $48.41.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/medidata-solutions-inc-mdso-president-vries-glen-michael-de-sells-7500-shares.html
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Wednesday, July 20th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The firm earned $114.60 million during the quarter, compared to the consensus estimate of $112.39 million. Medidata Solutions had a return on equity of 10.32% and a net margin of 5.29%. Medidata Solutions’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.22 earnings per share. On average, equities research analysts forecast that Medidata Solutions Inc. will post $1.01 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Capstone Asset Management Co. boosted its stake in shares of Medidata Solutions by 9.3% in the second quarter. Capstone Asset Management Co. now owns 19,570 shares of the company’s stock valued at $917,000 after buying an additional 1,670 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Medidata Solutions by 118.8% in the second quarter. BNP Paribas Arbitrage SA now owns 17,841 shares of the company’s stock valued at $836,000 after buying an additional 9,686 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Medidata Solutions during the first quarter valued at about $2,198,000. Granahan Investment Management Inc. MA boosted its stake in shares of Medidata Solutions by 83.3% in the first quarter. Granahan Investment Management Inc. MA now owns 231,344 shares of the company’s stock valued at $8,955,000 after buying an additional 105,100 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Medidata Solutions by 8.0% in the first quarter. Geode Capital Management LLC now owns 384,076 shares of the company’s stock valued at $14,867,000 after buying an additional 28,582 shares during the last quarter.
A number of brokerages have recently issued reports on MDSO. Wells Fargo & Co. lowered shares of Medidata Solutions from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 21st. Deutsche Bank AG lifted their price objective on Medidata Solutions from $56.00 to $58.00 and gave the company a “buy” rating in a report on Tuesday, September 13th. KeyCorp restated a “buy” rating on shares of Medidata Solutions in a report on Thursday, July 7th. Zacks Investment Research downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, Needham & Company LLC started coverage on Medidata Solutions in a report on Monday, July 11th. They issued a “buy” rating and a $55.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. Medidata Solutions currently has an average rating of “Buy” and an average target price of $54.09.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.